Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder
| Status: | Recruiting |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 11/30/-0001 |
| Start Date: | July 2012 |
| Contact: | Tara Lauriat, PhD |
| Email: | tlauriat@mclean.harvard.edu |
| Phone: | 617-789-2404 |
This is an ancillary study to a clinical trial that is being conducted at Massachusetts
General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy
of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399).
This observational study will involve magnetic resonance scans to examine brain chemistry
(neurotransmitter levels), brain activity, and functional connections between brain regions
before and after participating in the trial. The neurotransmitters of interest are
glutamate, glutamine, and GABA. Comparisons will be made between individuals who receive
ziprasidone and individuals who receive an inactive placebo. Differences between
participants who respond to standard antidepressants and those who require additional
medication will also be examined. All participants will have a baseline magnetic resonance
scan before starting medication. The second scan will be after 8 weeks of escitalopram
treatment for those who respond or following 8 weeks of escitalopram plus ziaprasidone or
placebo (16 weeks after starting) for those who do not respond to escitalopram alone.
Participants will complete standard rating scales for depression at each visit.
Inclusion Criteria:
- Aged 18-65
- Meets DSM-IV criteria for major depressive disorder
- Meets eligibility criteria for clinical trial of ziprasidone augmentation of
escitalopram
- Capable of providing informed consent
Exclusion Criteria:
- Meets exclusion criteria for augmentation clinical trial protocol
- Pregnancy or unwillingness to avoid pregnancy during trial
- Current or past psychosis or bipolar disorder
- Substance abuse or dependence in the past six months
- Clinically significant suicidality
- Unstable cardiovascular, hepatic, renal, respiratory, endocrine, neurological, or
hematological disease or uncontrolled seizures
- Use of a concomitant medication that acts on glutamate or GABA neurotransmission
- Contraindication to magnetic resonance imaging (metal implant or device, occupational
metal exposure, significant claustrophobia)
We found this trial at
1
site
Click here to add this to my saved trials
